La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

S2Medical Gestione

Gestione criteri di controllo 0/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Petter Sivlér

Amministratore delegato

n/a

Compenso totale

Percentuale dello stipendio del CEO	n/a
Mandato del CEO	11.6yrs
Proprietà del CEO	0.001%
Durata media del management	Nessun dato
Durata media del Consiglio di amministrazione	2.7yrs

Aggiornamenti recenti sulla gestione

Recent updates

AMMINISTRATORE DELEGATO

Petter Sivlér (39 yo)

11.6yrs

Mandato

Mr. Petter Sivlér Co-Founded S2Medical AB (publ) and has been its Chief Executive Officer from 2013.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Mårten Skog	Co-Founder	11.6yrs	Nessun dato	Nessun dato
Fredrik Skog	Chair of the Board	2.7yrs	Nessun dato	0.0098% SEK 1.2k
Miles Wright	Director	2.7yrs	Nessun dato	Nessun dato
Chadi Asaad	Director	2.7yrs	Nessun dato	Nessun dato
Patrick Sheehan	Director	2.7yrs	Nessun dato	Nessun dato

2.7yrs

Durata media

Consiglio di amministrazione esperto: Il consiglio di amministrazione di S2M non è considerato esperto (durata media del mandato 2.7 anni), il che suggerisce un nuovo consiglio.

S2Medical Gestione

Gestione criteri di controllo 0/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

No independent directors

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

No independent directors

Recent updates

First quarter 2024 earnings released

S2Medical AB (publ), Annual General Meeting, Jun 07, 2024

Full year 2023 earnings released: kr0.082 loss per share (vs kr1.24 loss in FY 2022)

New major risk - Shareholder dilution

Third quarter 2023 earnings released

Second quarter 2023 earnings released

S2Medical AB (publ) to Report Fiscal Year 2023 Results on Feb 20, 2024

New major risk - Shareholder dilution

First quarter 2023 earnings released

Full year 2022 earnings released: kr1.15 loss per share (vs kr1.35 loss in FY 2021)

S2Medical AB (publ) to Report Fiscal Year 2022 Results on Feb 22, 2023

S2Medical AB (publ) Announces the Positive Outcome of Antimicrobial Peptides Tests Against the Multi Resistant Bacteria

No independent directors

Third quarter 2022 earnings released

EPO Announces Intention to Approve Patenting of S2Medical AB's AMP Technology

S2Medical AB Announces Positive outcome from evaluation of Epiprotect in Saudi Arabia

S2Medical AB (publ) Updates Instagraft-Patent Approval in Israel

S2Medical AB (publ) Receives the Response from the European Patent Office That They Intend to Grant Patent Protection for the Company's Instagraft Technology Within Around Forty European Countries

S2Medical AB (Publ) Announces Appointment of Ingvild Thiry as Chief Financial Officer

First quarter 2022 earnings released

No independent directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Third quarter 2021 earnings: Revenues in line with analyst expectations

Second quarter 2021 earnings released

First quarter 2021 earnings released

Full year 2020 earnings released: kr1.33 loss per share (vs kr1.63 loss in FY 2019)

New 90-day low: kr7.50

New 90-day low: kr7.98

S2Medical AB (publ) (OM:S2M) entered into an agreement to acquire Curenc AB.

New 90-day high: kr9.69

Earnings released

AMMINISTRATORE DELEGATO

Mandato

Membri del Consiglio di amministrazione

Durata media